<h4>Purpose</h4>We report a novel side effect of Crizotinib, an oral ALK inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with activating rearrangement of EML4-ALK. This evidence concerns the gene EML4 and non-small cell lung carcinoma.